drug · antibody
tezepelumab
Marketedupdated 5mo agoby $AMGN AMGEN INC🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 2Antibody drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 6 investigational indications.
indications
investigational
Asthma
targets
Thymic stromal lymphopoietin
all catalysts(4)
approval · 4
Dec 17, 2021
approval
$AZN166.15-0.26%
TEZSPIRE (TEZEPELUMAB-EKKO) — FDA approval
tezepelumab
→
Feb 1, 2023
approval
$AZN166.15-0.26%
TEZSPIRE (TEZEPELUMAB-EKKO) — FDA approval
tezepelumab
→
May 26, 2023
approval
$AZN166.15-0.26%
TEZSPIRE (TEZEPELUMAB-EKKO) — FDA approval
tezepelumab
→
Oct 17, 2025
approval
$AZN166.15-0.26%
TEZSPIRE (TEZEPELUMAB-EKKO) — FDA approval
tezepelumab
→
Trials studying tezepelumab
- phase3A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
- —Tezspire Cardiac Events PASS
- —Observational Study on the Clinical Profile of Patients With Uncontrolled Severe Asthma Treated With Tezepelumab in Italy
- phase3Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab
- phase3Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis
- phase3A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab
- phase3A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
- phase3A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
News(4)
- AZ's R&D chief Barr touts internal 'science success story' after IL-33 antibody's stellar showing in COPDWith a detailed data drop that AstraZeneca’s R&D chief describes as an internal “science success story,” the British Big Pharma has secured an FDA priority review for what it believes could become…fiercebiotech · 20d ago
- AstraZeneca, Amgen poised to challenge Dupixent’s reign with esophagitis winEven without specific Phase 3 data yet revealed, analysts see AstraZeneca and Amgen’s Tezspire as a potential threat for Dupixent in eosinophilic esophagitis.biospace · 1mo ago
- New data could widen use of AstraZeneca, Amgen immune disease drugTezspire succeeded in a study in eosinophilic esophagitis, which could become the drug’s third approved indication and unlock what’s viewed as a blockbuster opportunity.biopharma_dive · 1mo ago
- AstraZeneca, Amgen notch another late-stage win for Tezspire, this time in esophagitisAstraZeneca and Amgen co-develop and co-commercialize Tezspire under an April 2012 agreement. The partners are now planning another FDA submission for the asthma drug, which received an expansion i…biospace · 1mo ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that